Abstract 381P
Background
Oral squamous cell carcinoma (OSCC) is highly prevalent in South-East Asia including Indonesia. Recurrence and early mortality in OSCC patients cause significant health burden. Subclassification of patients with high risks of locoregional recurrence and early death is beneficial for planning of treatment intensification and surveillance.
Methods
Formalin-fixed paraffin embedded (FFPE) tissues of OSCC were immuno-stained and analyzed for p16 expression. Semi-quantitative German scoring system for p16 was used. Risk factors and clinical parameters of OSCC patients were collected and compared to identify factors associated with recurrences and overall survival.
Results
OSCC recurrences and mortality were observed in in 82% and 78% patients (N=60) after a median follow-up of 32 months. Larger tumor size (T3 and T4) was significantly associated with both recurrences and mortality (OR = 3.967,95% CI = 1.007-15.618 and OR = 5.885, 95% CI = 1.541-22.47, respectively). Positive p16 staining was observed in 31% of tumors. Patients with p16 -positive expression were significantly associated with longer recurrence-free and overall survivals (medians of recurrence-free survivals were 31.2 vs 19.0 months, P=0.038 and overall survivals were 39.0 vs 28.8 months, P=0.048; respectively). Other clinical variables including early stages, negative cervical nodes, non-keratinizing tumors, and negative surgical margin status were significantly associated with longer recurrence-free and survivals (log-rank tests, P<0.05).
Conclusions
P16 -positive staining, early stages, positive cervical lymph node infiltration, and positive surgical margins are associated with better prognosis in OSCC patients. The study emphasizes the importance of early detection and the potential use of p16 and other clinical markers as prognostic markers in OSCC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
S. L. Anwar.
Funding
Universitas Gadjah Mada.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
528P - Socioeconomic determinants of access to standard-of-care treatments in advanced and metastatic NSCLC in Hong Kong: A territory-wide study
Presenter: Ka Man Cheung
Session: Poster Display
Resources:
Abstract